August 14, 2022



First Patient Gets Dose in Pfizer’s Oral COVID-19 Drug Trial

The Epoch Times

By Zachary Stieber

September 1, 2021 Updated: September 1, 2021


The first patient got dosed in a clinical trial analyzing Pfizer’s oral COVID-19 drug, the company announced Wednesday.

The phase 2/3 study is analyzing a protease inhibitor currently known as PF-07321332. The drug is meant to combat COVID-19 in patients who experience symptoms from the disease but do not require hospital care.

The randomized, double-blind trial will enroll about 1,140 participants, approximately half of whom will receive a placebo. The participants will get the drug or the placebo every 12 hours orally for five days.

Read more…

Super Sleuth